← Back to Search

Cognitive Training + Brain Stimulation for Alcoholism

N/A
Recruiting
Led By Jazmin Camchong, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Clinical evidence for Wernicke-Korsakoff syndrome
Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness >30 min, HIV)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 months post-intervention
Awards & highlights

Summary

This trial is testing whether a combination of electrical brain stimulation and cognitive training can help people with alcohol addiction maintain abstinence. They will also look at whether genetic or epigenetic differences are associated with variation in how well people respond to the treatment.

Who is the study for?
This trial is for individuals with Alcohol Use Disorder (AUD) who are committed to staying in a treatment program and have been abstinent from alcohol. They must meet specific mental health criteria, not have other primary substance use disorders except caffeine or nicotine, and cannot have certain neurological conditions or contraindications for tDCS or MRI.Check my eligibility
What is being tested?
The TANGO study tests if combining brain stimulation (tDCS) targeting the DLPFC region with cognitive training can improve executive function and help maintain abstinence in AUD patients. It also explores how genetic profiles might influence treatment response.See study design
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site, itching, tingling, headache, fatigue, nausea. Cognitive training is generally safe but could potentially cause temporary mental fatigue.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with Wernicke-Korsakoff syndrome.
Select...
I have a condition or received treatment that affected my nervous system.
Select...
I have had a head injury with a skull fracture or was unconscious for over 30 minutes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 months post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 months post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in D-KEFS Color Word score
Change in D-KEFS Trail Making (1-5) score
Change in D-KEFS Verbal Frequency score
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Participants receiving active transcranial direct current stimulation (tDCS)Experimental Treatment2 Interventions
Participants in this group will receive 5 sessions of active transcranial direct current stimulation (tDCS) to dorsolateral prefrontal cortex (DLPFC) while in the Lodging Plus treatment program and then 5 remote sessions of active tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.
Group II: Participants receiving active and sham active transcranial direct current stimulation (tDCS)Placebo Group2 Interventions
Participants in this group will receive 5 sessions of sham-tDCS sessions while in the Lodging Plus treatment program and then 5 remote sessions of active-tDCS to DLPFC after discharge from the treatment program. All participants will engage in executive functioning tasks for cognitive training during tDCS intervention (active or sham) to prime the engagement of the nucleus accumbens prefrontal cortex circuit. All participants will complete 4 MRI sessions. Craving measures will be collected before the first and after the last day of tDCS sessions. Follow-up interviews will be conducted monthly during a 4-month follow-up period after intervention completion to query relapse status. The first two follow-up interviews, at approximately 1- and 2-months post-intervention, will also include collection of cognition data.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulation technique that targets the dorsolateral prefrontal cortex (DLPFC) to improve executive functioning and support long-term abstinence in patients with Alcohol Use Disorder (AUD). By modulating neural activity in the DLPFC, tDCS enhances cognitive control and decision-making processes, which are often impaired in individuals with AUD. This improvement in executive functioning helps patients resist cravings and reduces the likelihood of relapse. Other common treatments for alcoholism include medications like naltrexone, which blocks opioid receptors to reduce the rewarding effects of alcohol, and acamprosate, which stabilizes brain chemistry to decrease withdrawal symptoms. Behavioral therapies, such as cognitive-behavioral therapy (CBT), focus on changing drinking behaviors and developing coping strategies. Understanding these mechanisms is crucial for tailoring effective treatment plans and improving outcomes for alcoholism patients.

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,395 Previous Clinical Trials
1,553,285 Total Patients Enrolled
9 Trials studying Alcoholism
2,085 Patients Enrolled for Alcoholism
Jazmin Camchong, PhDPrincipal InvestigatorUniveristy of Minnesota Department of Psychiatry & Behavioral Sciences
3 Previous Clinical Trials
104 Total Patients Enrolled
1 Trials studying Alcoholism
86 Patients Enrolled for Alcoholism

Media Library

Executive Function Focused Cognitive Training Clinical Trial Eligibility Overview. Trial Name: NCT05062369 — N/A
Alcoholism Clinical Trial 2023: Executive Function Focused Cognitive Training Highlights & Side Effects. Trial Name: NCT05062369 — N/A
Executive Function Focused Cognitive Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05062369 — N/A
Alcoholism Research Study Groups: Participants receiving active and sham active transcranial direct current stimulation (tDCS), Participants receiving active transcranial direct current stimulation (tDCS)
~13 spots leftby Sep 2025